Chinese pharmaceutical group selling branded generics and innovative drugs in oncology, CNS and anti-infection.
Chinese pharmaceutical group selling branded generics and innovative drugs in oncology, CNS and anti-infection.
Sells to Chinese hospitals, mostly through distributors, and its older branded generics face price pressure from state bulk-buying tenders. Newer innovative drugs carry the shift in mix, and licensing deals with other drugmakers add upfront and milestone payments to product income.
In one line: A mid-size Chinese pharma mixing generics and specialty drugs.
Moat: narrow (brand, distribution). Established hospital sales network and legacy branded-generic portfolio.
Headquarters: Nanjing, China · Founded: 1995 · Employees: 7,038
Size Simcere Pharmaceutical (2096.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $3.42B, the 310th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$10.42 on 18 Nov 2026.
Performance Over six months the shares fell 5.3%, against +3.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 27.2% over the last twelve months (peer median +3.6%); the operating margin is 17.8% (peer median 12.2%).
Valuation It trades at 13.5× forward earnings against a peer median of 18.2× (5th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.1 points above its cost of capital (6.7% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$9.76B | HK$8.38B | HK$7.19B | HK$7.30B | HK$7.35B |
| Revenue growth | — | +17% | -1% | -1% | — |
| Gross profit | HK$8.09B | HK$6.84B | HK$5.77B | HK$5.51B | HK$5.81B |
| EBITDA | HK$2.20B | HK$1.75B | HK$1.31B | HK$944M | HK$834M |
| Net income | HK$1.76B | HK$1.46B | HK$783M | HK$790M | HK$1.08B |
| Free cash flow | HK$2.47B | HK$1.84B | HK$1.19B | -HK$47.3M | HK$1.48B |
| Capital expenditure | HK$1.34B | HK$935M | HK$841M | HK$1.08B | HK$788M |
| Total debt | n/a | HK$1.33B | HK$1.32B | HK$1.67B | HK$1.81B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Simcere Pharmaceutical 2096.HK | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% |
| China Resources Pharmaceutical 3320.HK | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% |
| Livzon Pharmaceutical 1513.HK | $3.73B | -9% | -10% | 19% | 11.3× | -7.0% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2096.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.8% | +2.9% | 6th lowest of 21 |
| 6-month return | -5.3% | +3.4% | 7th lowest of 20 |
| Distance from 52-week high | -27.5% | -18.6% | 9th lowest of 21 |
| Revenue growth (TTM) | +27.2% | +3.6% | 5th highest of 18 |
| Operating margin | 17.8% | 12.2% | 6th highest of 16 |
| Forward P/E | 13.5× | 18.2× | 5th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | -3.4% | -3.1% | 6th least demanding of 11 |
| Growth delivered (Del g) | +10.6% | +4.9% | 3rd highest of 11 |
| Hurdle (Req g minus delivered) | -14.0 pp | -6.0 pp | 4th least demanding of 11 |
| ROIC minus cost of capital | +9.1 pp | +4.0 pp | 5th highest of 17 |
| EV / EBITDA | 11.3× | 30.7× | 3rd cheapest of 8 |
| Net debt / EBITDA | -0.8× | 2.6× | 2nd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Shanghai Junshi Biosciences 688180.SS | China | $3.48B | -31% | +29% | -15% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% | -9.6% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 11.3× | -7.0% | +2.0% |